WallStSmart

Alcon AG (ALC)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Thermo Fisher Scientific Inc generates 328% more annual revenue ($44.56B vs $10.40B). TMO leads profitability with a 15.0% profit margin vs 9.4%. ALC appears more attractively valued with a PEG of 1.70. TMO earns a higher WallStSmart Score of 59/100 (C).

ALC

Hold

49

out of 100

Grade: D+

Growth: 4.7Profit: 5.0Value: 7.3Quality: 7.3
Piotroski: 4/9

TMO

Buy

59

out of 100

Grade: C

Growth: 4.7Profit: 7.0Value: 7.3Quality: 6.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ALCSignificantly Overvalued (-489.8%)

Margin of Safety

-489.8%

Fair Value

$13.46

Current Price

$75.26

$61.80 premium

UndervaluedFair: $13.46Overvalued
TMOSignificantly Overvalued (-27.5%)

Margin of Safety

-27.5%

Fair Value

$384.82

Current Price

$490.77

$105.95 premium

UndervaluedFair: $384.82Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ALC2 strengths · Avg: 8.5/10
Debt/EquityHealth
0.249/10

Conservative balance sheet, low leverage

Price/BookValuation
1.7x8/10

Reasonable price relative to book value

TMO3 strengths · Avg: 8.3/10
Market CapQuality
$182.14B9/10

Large-cap with strong market position

Operating MarginProfitability
21.2%8/10

Strong operational efficiency at 21.2%

Free Cash FlowQuality
$2.99B8/10

Generating 3.0B in free cash flow

Areas to Watch

ALC4 concerns · Avg: 3.3/10
PEG RatioValuation
1.704/10

Expensive relative to growth rate

P/E RatioValuation
37.5x4/10

Premium valuation, high expectations priced in

Return on EquityProfitability
4.5%3/10

ROE of 4.5% — below average capital efficiency

EPS GrowthGrowth
-22.2%2/10

Earnings declined 22.2%

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

P/E RatioValuation
27.6x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ALC

The strongest argument for ALC centers on Debt/Equity, Price/Book.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap, Operating Margin, Free Cash Flow.

Bear Case : ALC

The primary concerns for ALC are PEG Ratio, P/E Ratio, Return on Equity.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

TMO carries more volatility with a beta of 0.97 — expect wider price swings.

ALC is growing revenue faster at 8.6% — sustainability is the question.

TMO generates stronger free cash flow (3.0B), providing more financial flexibility.

Monitor MEDICAL INSTRUMENTS & SUPPLIES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TMO scores higher overall (59/100 vs 49/100). Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Alcon AG

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Alcon, Inc., an eye care company, researches, develops, manufactures, distributes and sells eye care products for eye care professionals and their patients around the world. The company is headquartered in Geneva, Switzerland.

Visit Website →

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?